| __timestamp | CRISPR Therapeutics AG | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 91733000 |
| Thursday, January 1, 2015 | 13403000 | 87644000 |
| Friday, January 1, 2016 | 31056000 | 92365000 |
| Sunday, January 1, 2017 | 35845000 | 85656000 |
| Monday, January 1, 2018 | 48294000 | 88196000 |
| Tuesday, January 1, 2019 | 63488000 | 89971000 |
| Wednesday, January 1, 2020 | 88208000 | 93413000 |
| Friday, January 1, 2021 | 102802000 | 91355000 |
| Saturday, January 1, 2022 | 102464000 | 113676000 |
| Sunday, January 1, 2023 | 76162000 | 198366000 |
| Monday, January 1, 2024 | 72977000 | 218935000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology and pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. CRISPR Therapeutics AG and Taro Pharmaceutical Industries Ltd. offer a fascinating comparison in this regard. From 2014 to 2023, Taro consistently outspent CRISPR in SG&A costs, with Taro's expenses peaking at nearly 219% higher than CRISPR's in 2023. However, CRISPR's expenses grew significantly over the years, increasing by over 1,400% from 2014 to 2021, before a slight decline in 2023. Meanwhile, Taro's expenses remained relatively stable, with a notable spike in 2023. This data suggests that while Taro maintains a steady approach, CRISPR is rapidly expanding its operational scale. The absence of data for CRISPR in 2024 leaves room for speculation on its future cost management strategies.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG Trends and Insights
United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing CRISPR Therapeutics AG and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?